Human Treg responses allow sustained recombinant adeno-associated virus–mediated transgene expression
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Recombinant adeno-associated virus (rAAV) vectors have shown promise for the treatment of several diseases; however, immune-mediated elimination of transduced cells has been suggested to limit and account for a loss of efficacy. To determine whether rAAV vector expression can persist long term, we administered rAAV vectors expressing normal, M-type α-1 antitrypsin (M-AAT) to AAT-deficient subjects at various doses by multiple i.m. injections. M-specific AAT expression was observed in all subjects in a dose-dependent manner and was sustained for more than 1 year in the absence of immune suppression. Muscle biopsies at 1 year had sustained AAT expression and a reduction of inflammatory cells compared with 3 month biopsies. Deep sequencing of the TCR Vβ region from muscle biopsies demonstrated a limited number of T cell clones that emerged at 3 months after vector administration and persisted for 1 year. In situ immunophenotyping revealed a substantial Treg population in muscle biopsy samples containing AAT-expressing myofibers. Approximately 10% of all T cells in muscle were natural Tregs, which were activated in response to AAV capsid. These results suggest that i.m. delivery of rAAV type 1-AAT (rAAV1-AAT) induces a T regulatory response that allows ongoing transgene expression and indicates that immunomodulatory treatments may not be necessary for rAAV-mediated gene therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Regulatory T cells (Treg) modulate immune tolerance towards transgene product and capsid that are vital to durable expression of therapeutic protein (16, 17).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [17]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This long-term expression was attributed to the induction of regulatory T cells (Tregs) in the muscles of AAV-injected patients.”
From Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells (2021) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“whereas muscle-directed AAV gene therapy clinical trials have shown long-lived transgene expression and induction of Tregs.7,8,11,51”
From Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells (2021) · cites this paper as [11]
In the citing paper
“Tolerance induction and long-term expression of transgene in local muscle-directed AAV gene therapy was attributed to Tregs due to their ability to suppress immune responses [92].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [92]
In the citing paper
“Infiltration of CD4+ forkhead box P3+ (FoxP3) T cells, in addition to CD8+ T cells, was reported in α1-antitrypsin (AAT) deficiency and Glybera studies [92, 93].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [92]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378 · cited 1×
“The long-lasting presence of rAAV1 capsid may in some ways mimic a chronic viral infection, which has been shown to induce Treg responses (17) along with what has been termed “exhausted” T cells.”
BackgroundRestoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986 · cited 2×
“Interestingly, expression of PD-1 and PD-L1, which is associated with chronic viral infection and exhausted T cell responses (18–20), was also observed in many of the inflammatory foci of the rAAV-injected muscles.”
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864 · cited 2×
“(6), in a liver-directed hemophilia B trial, a modest immune modulation (60 mg prednisolone daily with tapering and discontinuation over 4 to 7 weeks) was sufficient to enhance gene expression and decrease transaminase elevation.”
Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide
Jordan, M. S., Boesteanu, A., Reed, A. J., Petrone, A. L., Holenbeck, A. E., Lerman, M. A., Naji, A., & Caton, A. J. (2001) · Nature Immunology · doi:10.1038/86302 · Cited by 1,660 · cited 1×
“It is known that natural Tregs (CD4+CD25+FOXP3+) arise in the thymus during development and are thought to possess T cell receptors specific for self antigens (26).”
Comprehensive assessment of T-cell receptor β-chain diversity in αβ T cells
Robins, H. S., Campregher, P. V., Srivastava, S. K., Wacher, A., Turtle, C. J., Kahsai, O., Riddell, S. R., Warren, E. H., & Carlson, C. S. (2009) · Blood · doi:10.1182/blood-2009-04-217604 · Cited by 1,122
Redefining Chronic Viral Infection
Virgin, H. W., Wherry, E. J., & Ahmed, R. (2009) · Cell · doi:10.1016/j.cell.2009.06.036 · Cited by 1,031
Hauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954
Self-citationCd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748 · cited 1×
“However, the significance of anti-capsid effector T cell responses is unclear, and at least some studies have suggested that they target transduced cells and limit the duration of transgene expression (9, 10).”
BackgroundLeWitt, P. A., Rezai, A. R., Leehey, M. A., Ojemann, S. G., Flaherty, A. W., Eskandar, E. N., Kostyk, S. K., Thomas, K., Sarkar, A., Siddiqui, M. S., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70039-4 · Cited by 681
Cited by
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Immune Responses to Viral Gene Therapy Vectors
Shirley, J. L., de Jong, Y. P., Terhorst, C., & Herzog, R. W. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.001 · Cited by 788
“Moreover, CD4CD25FoxP3 regulatory T cells (Tregs) infiltrated the tissue and likely contributed to the resolution of this immune response, while CD8 T cells acquired a phenotype resembling exhausted T cells.(62) Similar observations were made in muscle gene transfer for lipoprotein lipase deficiency.”
BackgroundAAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer
Costa Verdera, H., Kuranda, K., & Mingozzi, F. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.12.010 · Cited by 641
Greene, C. M., Marciniak, S. J., Teckman, J., Ferrarotti, I., Brantly, M. L., Lomas, D. A., Stoller, J. K., & McElvaney, N. G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.51 · Cited by 324
Self-citationKeeler, A. M., & Flotte, T. R. (2019) · Annual Review of Virology · doi:10.1146/annurev-virology-092818-015530 · Cited by 322
Self-citationUnraveling the complex story of immune responses to AAV vectors trial after trial.
Vandamme, C., Adjali, O., & Mingozzi, F. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.150 · Cited by 234
“On the other hand, it has been suggested that persisting intact capsid may also mimic a chronic viral infection and promote tolerance maintenance via induction or Tregs and expression of PD1/PDL1.(4,69) Ideally, the development of new immunosuppressive or immunomodulatory strategies for future clinical applications sh…”
BackgroundInfluentialGene Therapy for Duchenne Muscular Dystrophy
Elangkovan, N., & Dickson, G. (2021) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-210678 · Cited by 196
“, 2013 [76] also reported persistent, long-term transgene expression for up to 12 months and as such, immunomodulation of T cell populations may not be needed for muscle-directed AAV gene delivery.”
BackgroundMingozzi, F., & High, K. A. (2017) · Annual Review of Virology · doi:10.1146/annurev-virology-101416-041936 · Cited by 206
Hakim, C. H., Kumar, S. R. P., Pérez-López, D. O., Wasala, N. B., Zhang, D., Yue, Y., Teixeira, J., Pan, X., Zhang, K., Million, E. D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26830-7 · Cited by 175
Adeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery
Nidetz, N. F., McGee, M. C., Tse, L. V., Li, C., Cong, L., Li, Y., & Huang, W. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107453 · Cited by 174
Durability of transgene expression after rAAV gene therapy
Muhuri, M., Lévy, D., Schulz, M., McCarty, D. M., & Gao, G. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.03.004 · Cited by 172
“The group also identified intact capsids up to 1 year post-administration, potentially explaining the sustained presence of Tregs and exhausted T cells within the injected muscle, as would be expected during a chronic infection.(124) After 5 years, these patients have sustained expression of theAAT transgene and conti…”
BackgroundImmunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer
Arjomandnejad, M., Dasgupta, I., Flotte, T. R., & Keeler, A. M. (2023) · BioDrugs · doi:10.1007/s40259-023-00585-7 · Cited by 159
“Tolerance induction and long-term expression of transgene in local muscle-directed AAV gene therapy was attributed to Tregs due to their ability to suppress immune responses [92].”
BackgroundSelf-citationImmunity to CRISPR Cas9 and Cas12a therapeutics
Chew, W. L. (2018) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1408 · Cited by 147
“Treg-mediated immune tolerance(224) can also allow sustained gene therapy efficacy in humans.(225) These examples run contrary to the intuition that lower Cas9/Cas12a protein expression would necessarily lead to safer treatment.”
Ferreira, V., Twisk, J., Kwikkers, K., Aronica, E., Brisson, D., Methot, J., Petry, H., & Gaudet, D. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.169 · Cited by 137
“The data presented in this study support the findings reported by Mueller et al. (2013) and suggest that such mechanisms implicating T cell anergy and Tregs may occur after AAV-mediated gene transfer to muscle.”
Alipogene Tiparvovec: A Review of Its Use in Adults with Familial Lipoprotein Lipase Deficiency
Scott, L. J. (2015) · Drugs · doi:10.1007/s40265-014-0339-9 · Cited by 144
Rogers, G. L., Shirley, J. L., Zolotukhin, I., Kumar, S. R. P., Sherman, A., Perrin, G. Q., Hoffman, B. E., Srivastava, A., Basner-Tschakarjan, E., Wallet, M. A., et al. (2017) · Blood · doi:10.1182/blood-2016-11-751040 · Cited by 131
Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper
Yang, T., Braun, M., Lembke, W., McBlane, F., Kamerud, J., DeWall, S. L., Tarcsa, E., Fang, X., Hofer, L., Kavita, U., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.07.018 · Cited by 136
Challenges Posed by Immune Responses to AAV Vectors: Addressing Root Causes
Hamilton, B. A., & Wright, J. F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.675897 · Cited by 117
5 Year expression and neutrophil defect repair after gene therapy in alpha-1 antitrypsin deficiency
Mueller, C., Gernoux, G., Gruntman, A. M., Borel, F., Reeves, E. P., Calcedo, R., Rouhani, F. N., Yachnis, A., Humphries, M., Campbell-Thompson, M., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.029 · Cited by 112
“Early time points previously reported in Mueller et al.(18) Molecular Therapy”
BackgroundMethodResultSelf-citationNanocarriers in Gene Therapy: A Review
Xu, H., Li, Z., & Si, J. (2014) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2014.2044 · Cited by 106
Cell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions
Basner-Tschakarjan, E., & Mingozzi, F. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00350 · Cited by 95
“In some cases, detection of capsid T cell activation in PBMC correlated with lack of transgene expression in vector injected muscle (89, 91); while in other studies the detection of capsid T cells in PBMC seemed to have no effect on transgene persistence (28).”
BackgroundResultInfluentialEditing out five Serpina1 paralogs to create a mouse model of genetic emphysema
Borel, F., Sun, H., Zieger, M., Cox, A., Cardozo, B., Li, W., Oliveira, G., Davis, A., Gruntman, A., Flotte, T. R., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1713689115 · Cited by 98
Self-citationImmune Response Mechanisms against AAV Vectors in Animal Models
Martino, A. T., & Markusic, D. M. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.12.008 · Cited by 97
“Analysis of injected skeletal muscle revealed a reduction in infiltrating mononuclear cellular infiltrates, which consisted primarily of CD8 and FoxP3 regulatory T cells,(81) similar to what has been reported in human clinical trials investigating IM AAV gene delivery.(82,83) Infiltrating CD8 T cells displayed an exha…”
ResultErtl, H. C. J., & High, K. A. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.172 · Cited by 94
“81 It is possible that T cells induced by intramuscular injection of rAAV vectors are fundamentally different from those induced by systemic injection.”
T Cell-Mediated Immune Responses to AAV and AAV Vectors
Ertl, H. C. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.666666 · Cited by 88
Adeno-associated virus-mediated cancer gene therapy: Current status
Luo, J., Luo, Y., Sun, J., Zhou, Y., Zhang, Y., & Yang, X. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.10.045 · Cited by 96
Liver induced transgene tolerance with AAV vectors
Keeler, G. D., Markusic, D. M., & Hoffman, B. E. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2017.12.002 · Cited by 81
Chowdhury, E. A., Meno‐Tetang, G. M. L., Chang, H. Y., Wu, S., Huang, H. W., Jamier, T., Chandran, J. S., & Shah, D. K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.017 · Cited by 82
Hazari, Y., Bashir, A., Habib, M., Bashir, S., Habib, H., Qasim, M. A., Shah, N. N., Haq, E., Teckman, J. H., & Fazili, K. M. (2017) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2017.03.001 · Cited by 87
Calcedo, R., Somanathan, S., Qin, Q., Betts, M. R., Rech, A. J., Vonderheide, R. H., Mueller, C., Flotte, T. R., & Wilson, J. M. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1617726114 · Cited by 79
“Deep-sequencing analysis of the T-cell receptor β (TCRB) chain was performed using patient PBMCs to detect all possible rearranged genomic sequences and to determine T-cell receptor variable region b (TCR-Vb) use for each clone (Adaptive Biotechnologies) as described earlier (18).”
BackgroundMethodResultSelf-citationShirley, J. L., Keeler, G. D., Sherman, A., Zolotukhin, I., Markusic, D. M., Hoffman, B. E., Morel, L. M., Wallet, M. A., Terhorst, C., & Herzog, R. W. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.11.011 · Cited by 79
“In human skeletal muscle, capsid-specific CD8 T cells contributed to inflammation but failed to eliminate transgene expression, suggesting additional effects of the target tissue.(65)”
BackgroundBorel, F., Tang, Q., Gernoux, G., Greer, C., Wang, Z., Barzel, A., Kay, M. A., Shultz, L. D., Greiner, D. L., Flotte, T. R., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.09.020 · Cited by 79
Self-citationA systematic review of immunosuppressive protocols used in AAV gene therapy for monogenic disorders
Vrellaku, B., Hassan, I. S., Howitt, R., Webster, C. P., Harriss, E., McBlane, F., Betts, C., Schettini, J. L., Lion, M., Mindur, J. E., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.07.016 · Cited by 84
“63,72 Currently, the European Medicines Agency 78 and FDA 79 require an evaluation of humoral immunity by determining both the titers and avidities of antibodies against the AAV transgene product during clinical development.”
In Vivo Genome Editing Partially Restores Alpha1-Antitrypsin in a Murine Model of AAT Deficiency
Song, C.-Q., Wang, D., Jiang, T., O'Connor, K., Tang, Q., Cai, L., Li, X., Weng, Z., Yin, H., Gao, G., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.225 · Cited by 75
“A transgenic mouse model for the study of AATD was generated in the 1980s and has been widely used for preclinical studies for gene therapy of AATDrelated disease.(10,11) A *14 kb human Z-AAT transgene was introduced into the germline of mice, resulting in a mouse strain (PiZ mice) that expresses artificially high lev…”
MethodSelf-citationAdeno-Associated Viruses (AAV) and Host Immunity – A Race Between the Hare and the Hedgehog
Rapti, K., & Grimm, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.753467 · Cited by 79
AAV9 Edits Muscle Stem Cells in Normal and Dystrophic Adult Mice
Nance, M. E., Shi, R., Hakim, C. H., Wasala, N. B., Yue, Y., Pan, X., Zhang, T., Robinson, C. A., Duan, S. X., Yao, G., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.06.012 · Cited by 79
“It has been shown that AAV particles can be detected in tissue years after infection.(41,42) We reasoned that prolonged incubation of the AAV vector in muscle in vivomight increase the chance of MuSC transduction.”
BackgroundYe, G.-J., Budzynski, E., Sonnentag, P., Nork, T. M., Miller, P. E., Sharma, A. K., Ver Hoeve, J. N., Smith, L. M., Arndt, T., Calcedo, R., et al. (2016) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2015.164 · Cited by 64
“2 · 10(14) total VG in a 70-kg person) in subjects with a1antitrypsin deficiency.(41,42) In conclusion, subretinal injection of rAAV2tYFPR1.”
BackgroundSelf-citationAssessment of Humoral, Innate, and T-Cell Immune Responses to Adeno-Associated Virus Vectors
Calcedo, R., Chichester, J. A., & Wilson, J. M. (2018) · Human Gene Therapy Methods · doi:10.1089/hgtb.2018.038 · Cited by 62
“32,33 Additional studies, including immunohistochemical staining at the site of gene expression (beyond the scope of this manuscript), are required to fully assess immunomediated toxicity.”
Self-citationCas9-directed immune tolerance in humans—a model to evaluate regulatory T cells in gene therapy?
Wagner, D. L., Peter, L., & Schmueck-Henneresse, M. (2021) · Gene Therapy · doi:10.1038/s41434-021-00232-2 · Cited by 63
Ex Vivo Expanded Autologous Polyclonal Regulatory T Cells Suppress Inhibitor Formation in Hemophilia
Sarkar, D., Biswas, M., Liao, G., Seay, H. R., Perrin, G. Q., Markusic, D. M., Hoffman, B. E., Brusko, T. M., Terhorst, C., & Herzog, R. W. (2014) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2014.30 · Cited by 62
Self-citationFuchs, S. P., & Desrosiers, R. C. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.68 · Cited by 61
Gardner, M. R., Fetzer, I., Kattenhorn, L. M., Davis-Gardner, M. E., Zhou, A. S., Alfant, B., Weber, J. A., Kondur, H. R., Martinez-Navio, J. M., Fuchs, S. P., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.01.004 · Cited by 60
Complexity of immune responses to AAV transgene products – Example of factor IX
Herzog, R. W. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2017.05.006 · Cited by 60
“Evidence has been provided that CD4+CD25+FoxP3+ regulatory T cells (Treg) can suppress immune responses to transgene product and to capsid in skeletal muscle [48, 49].”
BackgroundImmunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies
Chu, W. S., & Ng, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.658038 · Cited by 59
“Regulatory T cells (Treg) modulate immune tolerance towards transgene product and capsid that are vital to durable expression of therapeutic protein (16, 17).”
BackgroundNext-generation muscle-directed gene therapy by in silico vector design
Sarcar, S., Tulalamba, W., Rincón, M. Y., Tipanee, J., Pham, H. Q., Evens, H., Boon, D., Samara-Kuko, E., Keyaerts, M., Loperfido, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08283-7 · Cited by 61
Herzog, R. W. (2015) · Frontiers in Bioscience · doi:10.2741/4324 · Cited by 55
“Although more recent clinical trials for gene transfer to skeletal muscle have used AAV serotype 1 (AAV1) vectors due to their superior transduction capacity in myocytes, these early studies used AAV2 vectors (29-34).”
BackgroundRevisiting the “New” Inflammatory Toxicities of Adeno-Associated Virus Vectors
Flotte, T. R. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.29117.trf · Cited by 56
“7 Depending on the disease being targeted by gene therapy, anti-transgene immunity has also occasionally been a limiting factor.”
Self-citationDoerfler, P. A., Todd, A. G., Clément, N., Falk, D. J., Nayak, S., Herzog, R. W., & Byrne, B. J. (2016) · Human Gene Therapy · doi:10.1089/hum.2015.103 · Cited by 54
“Supporting previous studies, these data highlight the role of Tregs induced after hepatic gene transfer in amelioration of immune responses after gene transfer and how immune tolerance induction benefits systemic therapies.(34,35,58,82) COPACKAGED AAV9 VECTORS FOR POMPE DISEASE 55”
ResultBoisgerault, F., & Mingozzi, F. (2015) · Current Gene Therapy · doi:10.2174/1566523215666150630121750 · Cited by 54
Ye, G.-J., Budzynski, E., Sonnentag, P., Miller, P. E., Sharma, A. K., Ver Hoeve, J. N., Howard, K., Knop, D. R., Neuringer, M., McGill, T., et al. (2015) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2015.076 · Cited by 53
“We have previously used sBHK cells grown in medium containing fetal bovine serum to produce an rAAV1-CB-hAAT vector that was evaluated in patients with alpha-1 antitrypsin (AAT) deficiency.(21,32,33) The process used for purification of that vector employed a CIM Q column followed by an AVB column.”
Self-citationLeborgne, C., Latournerie, V., Boutin, S., Desgue, D., Quéré, A., Pignot, E., Collaud, F., Charles, S., Simon Sola, M., Masat, E., et al. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2018.03.004 · Cited by 53
“AAV gene transfer has resulted in several examples of success in human trials [7-14].”
BackgroundHumoral immune responses to AAV gene therapy in the ocular compartment
Whitehead, M., Osborne, A., Yu‐Wai‐Man, P., & Martin, K. (2021) · Biological Reviews · doi:10.1111/brv.12718 · Cited by 52
“Initiation of tolerance to AAV capsids in two clinical studies has been observed which appeared to be mediated by the induction of regulatory T-cell (Treg) responses in which signalling via the programmed cell death protein-1 (PD1) and its cognate ligand PDL-1 was implicated (Mueller et al., 2013; Ferreira et al., 201…”
Muhuri, M., Zhan, W., Maeda, Y., Li, J., Lotun, A., Chen, J., Sylvia, K., Dasgupta, I., Arjomandnejad, M., Nixon, T., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.674242 · Cited by 50
Gene Therapy for Alpha-1 Antitrypsin Deficiency Lung Disease
Chiuchiolo, M. J., & Crystal, R. G. (2016) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201506-344kv · Cited by 50
Evaluation of Cellular Immune Response to Adeno-Associated Virus-Based Gene Therapy
Gorovits, B., Azadeh, M., Buchlis, G., Fiscella, M., Harrison, T., Havert, M., Janetzki, S., Jawa, V., Long, B. R., Mahnke, Y. D., et al. (2023) · The AAPS Journal · doi:10.1208/s12248-023-00814-5 · Cited by 52
“Additionally, the Treg-mediated cytokines can suppress the inflammatory effects of CD4 + and CD8 + T cells to enable AAV-mediated gene transduction (7, 8).”
BackgroundThe curious case of AAV immunology
Keeler, A. M., Zhan, W., Ram, S., Fitzgerald, K. A., & Gao, G. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.037 · Cited by 52
Gernoux, G., Gruntman, A. M., Blackwood, M., Zieger, M., Flotte, T. R., & Mueller, C. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.004 · Cited by 44
“This was explained by the presence of muscle-infiltrated regulatory T cells (Tregs) 1 year post-vector delivery in addition toAAV capsid persistence in situ.(34) Tregs were also detected in lipoprotein-lipase-deficient (LPLD) patients(35) after intramuscular (IM) gene transfer, suggesting that cellular immune response…”
BackgroundMethodInfluentialSelf-citationRogers, G. L., Martino, A. T., Zolotukhin, I., Ertl, H. C., & Herzog, R. W. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-25 · Cited by 45
Understanding and Tackling Immune Responses to Adeno-Associated Viral Vectors
Verdera, H. C., Unzu, C., Valeri, E., Adriouch, S., González‐Aseguinolaza, G., Mingozzi, F., & Kajaste‐Rudnitski, A. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.119 · Cited by 47
“131,132 137 Because it is a local route of administration into a site long considered im-munopriviledged, many trials have not included T cell response assays.”
Guilbaud, M., Devaux, M., Couzinié, C., Le Duff, J., Toromanoff, A., Vandamme, C., Jaulin, N., Gernoux, G., Larcher, T., Moullier, P., et al. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.234 · Cited by 45
“The involvement of Tregs in muscle local tolerance was reported in two Phase I/II clinical trials for alpha anti-tryspin and lipoprotein lipase deficiencies and was associated with persisting gene expression.(43,57,60) In addition with regards to the transgene product, liver-directed gene transfer was shown to be asso…”
BackgroundArjomandnejad, M., Sylvia, K., Blackwood, M., Nixon, T., Tang, Q., Muhuri, M., Gruntman, A. M., Gao, G., Flotte, T. R., & Keeler, A. M. (2021) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2021.10.010 · Cited by 44
“Steroids are commonly used in AAV trials for broad immunosuppression; however, they do not specifically target capsid-specific T cells,65 and may also deplete Tregs.66 In contrast, AAV-CAR Tregs provide selective immune modulation activated specifically by AAV capsid, creating a local immunosuppressive environment in…”
ResultInfluentialSelf-citationRegulatory and Exhausted T Cell Responses to AAV Capsid
Gernoux, G., Wilson, J. M., & Mueller, C. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.022 · Cited by 44
Self-citationGougeon, M.-L., Poirier-Beaudouin, B., Ausseil, J., Zérah, M., Artaud, C., Heard, J.-M., Deiva, K., & Tardieu, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.655478 · Cited by 38
Muscle Structure Influences Utrophin Expression in mdx Mice
Banks, G. B., Combs, A. C., Odom, G. L., Bloch, R. J., & Chamberlain, J. S. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004431 · Cited by 44
Gene therapy with regulatory T cells: A beneficial alliance
Biswas, M., Kumar, S. R. P., Terhorst, C., & Herzog, R. W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00554 · Cited by 41
“Interestingly, CD4+CD25+FoxP3+ Tregs were found within the infiltrating cells (~10%) in vector-injected muscle and were associated with a time-dependent decrease in muscle inflammation, which may have prevented the destruction of transduced myofibers (82).”
BackgroundHerzog, R. W., Cooper, M., Perrin, G. Q., Biswas, M., Martino, A. T., Morel, L., Terhorst, C., & Hoffman, B. E. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2017.07.012 · Cited by 39
“These patients experienced prolonged inflammation at the site of gene transfer, including CD8 T cell infiltration, which eventually resolved when Tregs started to dominate the response [48, 49].”
Genetic Modification of the Lung Directed Toward Treatment of Human Disease
Sondhi, D., Stiles, K. M., De, B. P., & Crystal, R. G. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.152 · Cited by 36
TCRklass: A New K-String–Based Algorithm for Human and Mouse TCR Repertoire Characterization
Yang, X., Liu, D., Lv, N., Zhao, F., Liu, F., Zou, J., Chen, Y., Xiao, X., Wu, J., Liu, P., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400711 · Cited by 36
Harkins, A. L., Ambegaokar, P. P., & Keeler, A. M. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00435 · Cited by 39
“Immuno-suppressive cells, such as T-regulatory cells (Tregs) can also be induced to AAV capsid or transgene [22,23].”
Zhan, W., Muhuri, M., Tai, P. W. L., & Gao, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.673699 · Cited by 37
Dissociation of skeletal muscle for flow cytometric characterization of immune cells in macaques
Liang, F., Ploquin, A., Hernández, J. D., Fausther‐Bovendo, H., Lindgren, G., Stanley, D. A., Salvador, A., Brenchley, J. M., Koup, R. A., Loré, K., et al. (2015) · Journal of Immunological Methods · doi:10.1016/j.jim.2015.06.011 · Cited by 36
“The choice of model vaccine was further motivated by the fact that infiltration of immune cells as well as presence of antigen expressed by recombinant adenoviral vectors have previously been reported in human muscle biopsies using immunohistochemistry (Mueller et al., 2013).”
BackgroundEstablishment of two quantitative nested qPCR assays targeting the human EPO transgene
Neuberger, E. W. I., Perez, I. C., Guiner, C. L., Moser, D., Ehlert, T., Allais, M., Moullier, P., Simon, P. D., & Snyder, R. O. (2016) · Gene Therapy · doi:10.1038/gt.2016.2 · Cited by 34
Current status of gene therapy for α-1 antitrypsin deficiency
Loring, H. S., & Flotte, T. R. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.978854 · Cited by 34
“assessed the implications of the recruitment and proliferation of regulatory T cells on the long-term expression of AAT [60].”
BackgroundInfluentialSelf-citationProgress in Respiratory Gene Therapy
McLachlan, G., Alton, E. W. F. W., Boyd, A., Clarke, N. K., Davies, J. C., Gill, D. R., Griesenbach, U., Hickmott, J. W., Hyde, S. C., Miah, K. M., et al. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.172 · Cited by 33
“80 Delivery of BE loaded RNP linked to amphiphilic CPPs into the airways of rhesus monkeys to target airway epithelial cells achieved in vivo editing at the CCR5 locus with up to 5.3% efficiency, a level considered therapeutically relevant in CF 102 (Table 2).”
InfluentialHepatotoxicity in Adeno-Associated Viral Vector Gene Therapy
Jagadisan, B., & Dhawan, A. (2023) · Current Hepatology Reports · doi:10.1007/s11901-023-00624-5 · Cited by 36
“Immunofluorescent staining of the capsid was demonstrated within myofibers of the muscle, mostly in distinct foci at the perinuclear region [54].”
Schnepp, B. C., Chulay, J. D., Ye, G., Flotte, T. R., Trapnell, B. C., & Johnson, P. R. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.136 · Cited by 32
“As part of the ongoing assessment of subjects in the trial, muscle biopsies were performed at 3 and 12 months after vector injection.(14,15) These unique biopsy samples afforded us the opportunity to quantify and analyze persisting rAAV1-AAT vector genomes.”
BackgroundMethodInfluentialSelf-citationImmune Responses to Muscle-Directed Adeno-Associated Viral Gene Transfer in Clinical Studies
Kumar, S. R. P., Duan, D., & Herzog, R. W. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.056 · Cited by 28
“24 The presence of AAV capsids long after vector injection may mimic a state of chronic viral infection.”
Moreau, A., Vandamme, C., Segovia, M., Devaux, M., Guilbaud, M., Tilly, G., Jaulin, N., Duff, J. L., Chérel, Y., Deschamps, J., et al. (2014) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2014.28 · Cited by 28
Hutt, J. A., Assaf, B. T., Bolon, B. N., Cavagnaro, J. A., Galbreath, E. J., Grubor, B., Kattenhorn, L. M., Romeike, A., & Whiteley, L. O. (2021) · Toxicologic Pathology · doi:10.1177/01926233211041962 · Cited by 28
Gene therapy for alpha-1 antitrypsin deficiency: an update
Pires-Ferreira, D., Gruntman, A. M., & Flotte, T. R. (2023) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2023.2183771 · Cited by 29
“8% of the target therapeutic level after the single IM administration [42].”
BackgroundSelf-citationNuclease-Mediated Gene Therapies for Inherited Metabolic Diseases of the Liver.
Te, B., Anglin, C. M., Bridges, P. H., & Cottle, R. N. (2017) · PubMed Central · Cited by 33
Vandamme, C., Xicluna, R., Hesnard, L., Devaux, M., Jaulin, N., Guilbaud, M., Le Duff, J., Couzinié, C., Moullier, P., Saulquin, X., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03110 · Cited by 23
“With over a 100 gene therapy clinical trials worldwide, sustained therapeutic effect has been achieved in the frame of a variety of inherited diseases such as Leber’s congenital amaurosis type 2 (1, 2), hemophilia B (3), M-type α-1 antitrypsin deficiency (4), or lipoprotein lipase deficiency (5).”
BackgroundCramer, M. L., Shao, G., Rodino-Klapac, L. R., Chicoine, L. G., & Martin, P. T. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.113 · Cited by 22
“Additional cellular mechanisms, for example the presence of infiltrating Treg cells, which can also express PD1 and PDL1, may also impact long-term AAV-mediated gene expression.(6,11,13,66) The persistence of inert CD8+ T cells observed following treatment with rAAV therapy is reminiscent of what has been seen in host…”
BackgroundRecombinant adeno-associated virus vectors in the treatment of rare diseases
Hastie, E. L., & Samulski, R. J. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1039511 · Cited by 25
“Interestingly, immunomodulation may affect initial transduction levels, but may not significantly impact transgene expression afterward [113].”
BackgroundYe, G.-J., Scotti, M. M., Thomas, D. L., Wang, L., Knop, D. R., & Chulay, J. D. (2014) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2014.060 · Cited by 21
“…TFF, diafiltered, and then sterile filtered through a 0.2 l m filter to generate the drug product. replication-incompetent rHSV, by the processes used to recover and purify the rAAV1-CB-hAAT vector that was evaluated in a recently completed clinical trial (Flotte et al. , 2011; Mueller et al. , 2013).”
InfluentialSelf-citationAlpha-1 Antitrypsin Investigations Using Animal Models of Emphysema
Ni, K., Serban, K. A., Batra, C., & Petrache, I. (2016) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201510-675kv · Cited by 21
Preclinical models to assess the immunogenicity of AAV vectors
Ertl, H. C. J. (2017) · Cellular Immunology · doi:10.1016/j.cellimm.2017.11.006 · Cited by 22
Bioengineered Viral Platform for Intramuscular Passive Vaccine Delivery to Human Skeletal Muscle
Paulk, N. K., Pekrun, K., Charville, G. W., Maguire, K., Wosczyna, M. N., Xu, J., Zhang, Y., Lisowski, L., Yoo, B., Vilches-Moure, J. G., et al. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.06.001 · Cited by 20
FSHD Therapeutic Strategies: What Will It Take to Get to Clinic?
Himeda, C. L., & Jones, P. L. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12060865 · Cited by 21
“The capsid can also trigger clearance of infected cells by cytotoxic T lymphocytes [107], an event that can be mitigated by Treg cells [108]; thus, autologous Treg cells may prove to be a useful adjuvant to in vivo gene therapies [109].”
BackgroundOrtved, K. F., Wagner, B., Calcedo, R., Wilson, J. M., Schaefer, D. M. W., & Nixon, A. J. (2015) · Human Gene Therapy · doi:10.1089/hum.2014.050 · Cited by 19
“35 T-regulatory responses were not evaluated in this study, although their role in AAV-mediated transgene expression was described by Mueller and colleagues, 36 in which long-term M-type a 1 - antitrypsin (M-ATT) expression was seen in the muscle of patients despite a T cell response.”
Self-citationInhibition of antigen presentation during AAV gene therapy using virus peptides
Shao, W., Chen, X., Samulski, R. J., Hirsch, M. L., & Li, C. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddx427 · Cited by 17
Experimental and investigational drugs for the treatment of alpha-1 antitrypsin deficiency
Pye, A., & Turner, A. M. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1672656 · Cited by 19
Pouzolles, M., Machado, A., Guilbaud, M., Irla, M., Gailhac, S., Barennes, P., Cesana, D., Calabria, A., Benedicenti, F., Sergé, A., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.08.029 · Cited by 17
Hahn, P. A., & Martins, M. A. (2023) · Journal of Virus Eradication · doi:10.1016/j.jve.2023.100316 · Cited by 15
Gruntman, A. M., & Flotte, T. R. (2015) · Human Gene Therapy Methods · doi:10.1089/hgtb.2015.086 · Cited by 15
“Interestingly, despite the presence of CD8-positive T-lymphocytes being present in the injected muscle at day 90, serum hAAT levels persisted in patients at stable levels for over 1 year without the need for immunosuppressive therapy.(25,29) Further characterization of the inflammatory infiltrate surrounding the myofi…”
BackgroundSelf-citationMultilineage transduction of resident lung cells in vivo by AAV2/8 for α1-antitrypsin gene therapy
Payne, J. G., Takahashi, A., Higgins, M. I., Porter, E. L., Suki, B., Balazs, A. B., & Wilson, A. A. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2016.42 · Cited by 15
Xicluna, R., Avenel, A., Vandamme, C., Devaux, M., Jaulin, N., Couzinié, C., Duff, J. L., Charrier, A., Guilbaud, M., Adjali, O., et al. (2024) · Human Gene Therapy · doi:10.1089/hum.2023.225 · Cited by 14
Muñoz-Melero, M., & Biswas, M. (2024) · Human Gene Therapy · doi:10.1089/hum.2023.227 · Cited by 14
“77 A further follow-up study conducted 5 years after gene transfer showed the persistence of Tregs and potentially exhausted AAV capsid-specific CD8 + T cells within the injected muscle.”
The murine lung as a factory to produce secreted intrapulmonary and circulatory proteins
Paul-Smith, M. C., Pytel, K. M., Gélinas, J., McIntosh, J., Pringle, I. A., Davies, L., Chan, M., Meng, C., Bell, R. V., Cammack, L., et al. (2018) · Gene Therapy · doi:10.1038/s41434-018-0025-8 · Cited by 14
SERCA2a overexpression improves muscle function in a canine Duchenne muscular dystrophy model
Kodippili, K., Hakim, C. H., Burke, M. J., Yue, Y., Teixeira, J. A., Zhang, K., Yao, G., Babu, G. J., Herzog, R. W., & Duan, D. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101268 · Cited by 13
“34,35 We would like to point out that the CMV promoter is not desirable for clinical translation because it may lead to untoward expression in non-muscle cells and contribute to the cellular response.”
Metadata
- Authors
- Mueller, C., Chulay, J. D., Trapnell, B. C., Humphries, M., Carey, B., Sandhaus, R. A., McElvaney, N. G., Messina, L., Tang, Q., Rouhani, F. N., Campbell-Thompson, M., Fu, A. D., Yachnis, A., Knop, D. R., Ye, G.-J., Brantly, M., Calcedo, R., Somanathan, S., Richman, L. P., Vonderheide, R. H., Hulme, M. A., Brusko, T. M., Wilson, J. M., & Flotte, T. R.
- Affiliations
- University of Massachusetts Chan Medical School (US)
- Applied Genetic Technologies (United States) (US)
- Cincinnati Children's Hospital Medical Center (US)
- National Jewish Health (US)
- Beaumont Hospital (IE)
- University of Florida Health (US)
- University of Pennsylvania (US)
- Corresponding author
- Flotte, Terence R.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2013-11-15
- Volume
- 123
- Issue
- 12
- Pages
- 5310-5318
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3859421
- OpenAlex
- W2087513462
- Cited by
- 169
- References
- 40
- Citations by year
- 2026: 5 · 2025: 13 · 2024: 14 · 2023: 9 · 2022: 9 · 2021: 19 · 2020: 9 · 2019: 16 · 2018: 10 · 2017: 23 · 2016: 11 · 2015: 17 · 2014: 13 · 2013: 1
- FWCI
- 9.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- The Journal of the American Medical Association (JAMA) Network (American Medical Association) (submittedVersion)
- Funders
- National Institutes of Health (UL1TR000161)
- U.S. Food and Drug Administration (R01FD003896)
- National Heart, Lung, and Blood Institute (R01HL069877, HL 69877)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- recombinant adeno-associated virus, AAV1, alpha-1 antitrypsin deficiency, regulatory T cells, natural regulatory T cells, transgene expression persistence, gene therapy, T cell receptor V beta repertoire, AAV capsid, intramuscular injection, immunomodulation, muscle fibers
- MeSH terms
- Dependovirus, alpha 1-Antitrypsin, Biopsy, Capsid, Clone Cells, Gene Expression Regulation, Genetic Vectors, Humans, Injections, Intramuscular, Lymphocyte Activation, Recombinant Fusion Proteins, Genetic Therapy, Gene Rearrangement, beta-Chain T-Cell Antigen Receptor, Receptors, Antigen, T-Cell, alpha-beta, Muscle, Skeletal, Transgenes, alpha 1-Antitrypsin Deficiency, T-Lymphocytes, Regulatory
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.